From an RNA-seq screen of 81 primary, treatment-naive, ER+ breast cancers from two neoadjuvant AI clinical trials (Table S1, NeoAI Trials), two PCR-validated ESR1 fusions were identified. Here, ESR1 is linked to breast carcinoma.